JP2018529698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529698A5 JP2018529698A5 JP2018515673A JP2018515673A JP2018529698A5 JP 2018529698 A5 JP2018529698 A5 JP 2018529698A5 JP 2018515673 A JP2018515673 A JP 2018515673A JP 2018515673 A JP2018515673 A JP 2018515673A JP 2018529698 A5 JP2018529698 A5 JP 2018529698A5
- Authority
- JP
- Japan
- Prior art keywords
- ezh2 inhibitor
- smarac4
- ezh2
- inhibitor according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233146P | 2015-09-25 | 2015-09-25 | |
| US62/233,146 | 2015-09-25 | ||
| US201562252188P | 2015-11-06 | 2015-11-06 | |
| US62/252,188 | 2015-11-06 | ||
| PCT/US2016/053673 WO2017053930A2 (en) | 2015-09-25 | 2016-09-26 | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529698A JP2018529698A (ja) | 2018-10-11 |
| JP2018529698A5 true JP2018529698A5 (enExample) | 2019-11-07 |
| JP7013369B2 JP7013369B2 (ja) | 2022-02-15 |
Family
ID=58387531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515673A Expired - Fee Related JP7013369B2 (ja) | 2015-09-25 | 2016-09-26 | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20180296563A1 (enExample) |
| EP (1) | EP3352761A4 (enExample) |
| JP (1) | JP7013369B2 (enExample) |
| KR (1) | KR20180054793A (enExample) |
| CN (2) | CN114533880B (enExample) |
| AU (2) | AU2016325643B2 (enExample) |
| CA (1) | CA2999898A1 (enExample) |
| EA (1) | EA201890801A1 (enExample) |
| IL (2) | IL258302A (enExample) |
| MX (2) | MX2018003663A (enExample) |
| SG (1) | SG10201908323TA (enExample) |
| WO (1) | WO2017053930A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| KR102021642B1 (ko) | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| CN108025191A (zh) | 2015-08-24 | 2018-05-11 | Epizyme股份有限公司 | 治疗癌症的方法 |
| MX2018003663A (es) * | 2015-09-25 | 2018-08-14 | Epizyme Inc | Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. |
| WO2017132518A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| WO2017214373A1 (en) * | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| AU2018217139A1 (en) * | 2017-02-02 | 2019-08-22 | Epizyme, Inc. | Cancer treatment modalities |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2018223030A1 (en) | 2017-06-02 | 2018-12-06 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN113874013A (zh) * | 2019-03-26 | 2021-12-31 | 转化药物开发有限责任公司 | 治疗卵巢恶性横纹肌样瘤和高钙血症型卵巢小细胞癌的方法 |
| CN114555112A (zh) * | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| US20230201213A1 (en) * | 2020-05-28 | 2023-06-29 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| CN115786261B (zh) * | 2022-11-28 | 2024-12-06 | 复旦大学附属妇产科医院 | 一种卵巢高钙血症型小细胞癌细胞系及其用途 |
| CN119215165B (zh) * | 2023-06-29 | 2026-03-27 | 复旦大学附属妇产科医院 | Plk1抑制剂在制备治疗卵巢高钙血症型小细胞癌的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011298987B2 (en) * | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012156463A1 (en) * | 2011-05-16 | 2012-11-22 | Ulrike Nuber | Novel cancer therapies and methods |
| HUE042271T2 (hu) * | 2012-03-12 | 2019-06-28 | Epizyme Inc | Emberi EZH2 inhibitorai és azok alkalmazási eljárásai |
| KR102117982B1 (ko) * | 2012-04-13 | 2020-06-03 | 에피자임, 인코포레이티드 | 암 치료용 병용 요법 |
| KR102021642B1 (ko) * | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| US20140120083A1 (en) * | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015103431A1 (en) * | 2013-12-31 | 2015-07-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function |
| SG10201808053XA (en) * | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| CN108025191A (zh) * | 2015-08-24 | 2018-05-11 | Epizyme股份有限公司 | 治疗癌症的方法 |
| MX2018003663A (es) * | 2015-09-25 | 2018-08-14 | Epizyme Inc | Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. |
-
2016
- 2016-09-26 MX MX2018003663A patent/MX2018003663A/es unknown
- 2016-09-26 KR KR1020187011111A patent/KR20180054793A/ko not_active Ceased
- 2016-09-26 AU AU2016325643A patent/AU2016325643B2/en not_active Ceased
- 2016-09-26 CA CA2999898A patent/CA2999898A1/en not_active Abandoned
- 2016-09-26 SG SG10201908323T patent/SG10201908323TA/en unknown
- 2016-09-26 US US15/762,839 patent/US20180296563A1/en not_active Abandoned
- 2016-09-26 CN CN202210048334.0A patent/CN114533880B/zh active Active
- 2016-09-26 CN CN201680063541.6A patent/CN108349958B/zh active Active
- 2016-09-26 JP JP2018515673A patent/JP7013369B2/ja not_active Expired - Fee Related
- 2016-09-26 WO PCT/US2016/053673 patent/WO2017053930A2/en not_active Ceased
- 2016-09-26 EA EA201890801A patent/EA201890801A1/ru unknown
- 2016-09-26 EP EP16849837.6A patent/EP3352761A4/en not_active Withdrawn
-
2018
- 2018-03-22 IL IL258302A patent/IL258302A/en unknown
- 2018-03-23 MX MX2022013390A patent/MX2022013390A/es unknown
-
2019
- 2019-10-04 US US16/593,010 patent/US20200138825A1/en not_active Abandoned
-
2020
- 2020-09-03 US US17/011,132 patent/US20210121470A1/en not_active Abandoned
-
2021
- 2021-02-09 IL IL280760A patent/IL280760A/en unknown
-
2022
- 2022-10-19 AU AU2022256115A patent/AU2022256115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6295081B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのアセチル化チューブリンの使用 | |
| JP2016169229A5 (enExample) | ||
| JP2018083821A5 (enExample) | ||
| JP6402393B2 (ja) | 抗悪性腫瘍剤組成物 | |
| JP2017511377A5 (enExample) | ||
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP6270481B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｇｌｕ−チューブリンの使用 | |
| JP2016539134A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| JP2020505426A5 (enExample) | ||
| JP2015509489A5 (enExample) | ||
| JP2016530495A5 (enExample) | ||
| JP6302673B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用 | |
| Scholz et al. | Novel host proteins and signaling pathways in enteropathogenic E. coli pathogenesis identified by global phosphoproteome analysis | |
| JP2016516074A5 (enExample) | ||
| JP2019511550A5 (enExample) | ||
| JP2013506836A (ja) | プロテインキナーゼｃｋ２介在性疾患のｃｋ２阻害剤に対する感受性および反応を予測するバイオマーカー | |
| JP2019527037A5 (enExample) | ||
| JP2009545526A5 (enExample) | ||
| Gahr et al. | Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma-review of the underlying molecular mechanisms and first case report | |
| US8288087B2 (en) | Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma | |
| Misra et al. | Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective | |
| WO2016172191A1 (en) | Compounds, compositions and methods for inhibiting cnksr1 | |
| Haluska et al. | 214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer |